CEP-37440

a focal adhesion kinase inhibitor

Also Known As:

2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5H-benzo(7)annulen-2-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aburto, Lucy D: 1 article (03/2016)
2.	Addya, Sankar: 1 article (03/2016)
3.	Alsalahi, Manal: 1 article (03/2016)
4.	Chervoneva, Inna: 1 article (03/2016)
5.	Cristofanilli, Massimo: 1 article (03/2016)
6.	Fernandez, Sandra V: 1 article (03/2016)
7.	Ott, Gregory R: 1 article (03/2016)
8.	Ruggeri, Bruce A: 1 article (03/2016)
9.	Salem, Israa: 1 article (03/2016)

Related Diseases

1.	Triple Negative Breast Neoplasms 03/24/2016 - "Cell proliferation assays were performed in the presence of several concentrations of CEP-37440 using IBC and triple-negative breast cancer non-IBC cell lines. "
2.	Inflammatory Breast Neoplasms 03/24/2016 - "The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells."
3.	Neoplasms (Cancer) 03/24/2016 - "In vivo, after 7 weeks of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, respectively. "
4.	Neoplasm Metastasis (Metastasis) 03/24/2016 - "None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis. "
5.	Breast Neoplasms (Breast Cancer) 03/24/2016 - "In vivo, after 7 weeks of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, respectively. "

Related Drugs and Biologics

1.	Focal Adhesion Protein-Tyrosine Kinases